Citations

Mayo Clinic

Showing 10 of 108551 citations.

American Society for Gastrointestinal Endoscopy–European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
Jirapinyo, Pichamol , Hadefi, Alia , Sullivan, Shelby , Thompson, Christopher C. , Patai, Árpád V. , Pannala, Rahul , Goelder, Stefan, Kushnir, Vladimir , Apovian, Caroline M., Chapman, Christopher G., Davidson, Paul , Kumbhari, Vivek , Esker, Janelle, Hucl, Tomáš , Schulman, Allison R. , Zelber‐Sagi, Shira , Bain, Paul , Huberty, Vincent , Barthet, Marc , Boškoski, Ivo , Donatelli, Gianfranco , Hayee, Bu , Pryor, Aurora Dawn , Maselli, Roberta , Pattou, François , Durieux, Valérie , Τriantafyllou, Κonstantinos , Thosani, Nirav C

Endoscopy | April 19, 2024 | Volume: 56 | Issue: 06 | Pages: 437-456

10.1055/a-2292-2494 | PMID 38641332 Get It

AbstractThis joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥30 kg/m2, or with a BMI of 27.0–29.9 kg/m2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
Kumar, Shaji , Mammadzadeh, Aytaj , Bolarinwa, Abiola , Elhaj, Mohammed, Bohra, Arwa , Bansal, Radhika , Khot, Amit , Ailawadhi, Sikander , Parrondo, Ricardo , Hayman, Suzanne R. , Warsame, Rahma , Kapoor, Prashant , Kourelis, Taxiarchis , Ailawadhi, Sikander , Parrondo, Ricardo D , Khot, Amit , Bolarinwa, Abiola B

No container title available | April 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4254335/v1 Get It

Abstract Three classes of BCMA-directed therapy (BDT) exist: antibody drug-conjugates (ADCs), CAR-T, and T-cell engagers (TCEs), each with distinct strengths and weaknesses. To aid clinicians in selecting between BDTs, we reviewed myeloma patients treated at Mayo Clinic with commercial or investigational BDT between 2018–2023. We identified 339 individuals (1-exposure = 297, 2-exposures = 38, 3-exposures = 4) who received 385 BDTs (ADC = 59, TCE = 134, CAR-T = 192), with median follow-up of 21-months. ADC recipients were older, with more lines of therapy (LOT), and penta-refractory disease. Compared to ADCs, CAR-T (aHR = 0.29, 95%CI = 0.20–0.43) and TCEs (aHR = 0.62, 95%CI = 0.43–0.91) had better progression-free survival (PFS) on analysis adjusted for age, the presence of extramedullary (EMD), penta-refractory disease, multi-hit high-risk cytogenetics, prior BDT, and the number of LOT in the preceding 1-year. Likewise, compared to ADCs, CAR-T (aHR = 0.28, 95%CI = 0.18–0.44) and TCEs (aHR = 0.60, 95%CI = 0.39–0.93) had superior overall survival. Prior BDT exposure negatively impacted all classes but was most striking in CAR-T, ORR 86% vs. 50% and median PFS 13-months vs. 3-months. Of relapses, 54% were extramedullary in nature, and a quarter of these cases had no history of EMD. CAR-T demonstrates superior efficacy and where feasible, should be the initial BDT. However, for patients with prior BDT or rapidly progressive disease, an alternative approach may be preferable.
Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer
Basourakos, Spyridon P. , An, Anjile , Davuluri, Meenakshi , Pinheiro, Laura C. , Awamlh, Bashir Al Hussein Al , Kensler, Kevin H. , Kensler, Kevin , Basourakos, Spyridon , Al Hussein Al Awamlh, Bashir , Borregales, Leonardo Daniel , Luan, Danny , Tamimi, Rulla M. , Hu, Jim C.

Urology Practice | April 19, 2024 | Volume: 11 | Issue: 3 | Pages: 538-546

10.1097/upj.0000000000000529 | PMID 38640417 Get It

ClC-1 Inhibition as a Novel Mechanism for Accelerating Recovery of Skeletal Muscle Function After Neuromuscular Block in an Experimental Rat Model
Skals, Marianne , Broch‐Lips, Martin , Skov, Martin , Riisager, Anders , Ceelen, Judith, Boer, Hans D. de

No container title available | April 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4157720/v1 Get It

Abstract Neuromuscular blocking agents (NMBAs) are commonly used to induce skeletal muscle relaxation during surgery. While muscle relaxation facilitates surgical procedures and tracheal intubation, adequate recovery of muscle function after surgery is required to support pulmonary function, and even mild residual neuromuscular block increases the risk of severe postoperative pulmonary complications. While recovery of muscle function after surgery involving NMBAs can be monitored and, in addition, be accelerated by use of current antagonists (reversal agents), there is a clear clinical need for a safe drug to antagonize all types of NMBAs. Here we show that inhibition of the skeletal muscle-specific chloride ion (Cl-) channel, the ClC-1 channel, markedly accelerates recovery of both single contraction (twitch) and physiologically important sustained contractions (tetanic) in a novel rat model mimicking NMBA-induced muscle block used during surgery. ClC-1 inhibition was found to reverse any NMBA with superior properties to existing reversal agents. This suggests ClC-1 inhibition as a novel mechanism for fast and efficacious reversal from neuromuscular block.
Health Impact of Alcohol Use in the United States
Keyes, Katherine M. , Martínez, Priscilla , Milam, Adam J. , Rehm, Jürgen , Milam, Adam J , Shield, Kevin , Naimi, Timothy S.

No container title available | April 19, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4224612/v1 Get It

Abstract Background Alcohol is consumed by an estimated 137.4 million people in the United States 12 years of age and older, and, as a result, is estimated to have caused about 140 thousand deaths among people 20 to 64 years of age each year from 2015 up to and including 2019. Methods The proposed proposed review of the evidence on alcohol’s impact to health aims to produce conclusions to inform the Dietary Guidelines for Americans, 2026–2030. A multi-method approach will be utilized to formulate conclusions on (i) weekly (i.e., average) thresholds to minimize long-term and short-term risks of morbidity and mortality, (ii) daily thresholds to minimize the short-term risk of injury or acute illness due to per occasion drinking, (iii) alcohol use among vulnerable populations (e.g., pregnant women), and (iv) situations and circumstances that are hazardous for alcohol use. To inform expert discussions, this project will also include a systematic review of existing low-risk drinking guidelines, a systematic review of meta-analyses which examine alcohol’s impact on key attributable disease and mortality outcomes, and of estimates of the lifetime absolute risk of alcohol-attributable mortality and morbidity based on a person’s sex and average level of alcohol use. The preliminary conclusions produced as a result of this project will undergo public consultation, and data from these consultations will be analyzed using both quantitative and qualitative methods. The results of the public consultations will be used to further revise and refine the project’s conclusions. Discussion This project will establish a scientific consensus concerning alcohol’s impact on health. This consensus is imperative for informing the upcoming Dietary Guidelines for Americans, 2026–2030, and for better informing individuals about the health risks associated with alcohol use.
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
DiNardo, Courtney D. , Roboz, Gail J. , Watts, Justin M. , Madanat, Yazan F. , Prince, Gabrielle T., Baratam, Praneeth , Botton, Stéphane de , Stein, Anthony S. , Foran, James M. , Arellano, Martha , Sallman, David A. , Marchione, Dylan M. , Patel, Prapti A. , Kapsalis, Stephanie M., Garcia‐Manero, Guillermo , Fathi, Amir T. , de Botton, Stéphane , Fathi, Amir T , DiNardo, Courtney , Roboz, Gail J , Madanat, Yazan , Hossain, Mohammad Sharif , Bai, Xiaofei

Blood Advances | April 19, 2024 | Volume: 8 | Issue: 15 | Pages: 4209-4220

10.1182/bloodadvances.2023012302 | PMID 38640348 Get It

Abstract Ivosidenib is a first-in-class mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor with efficacy and tolerability in patients with advanced mIDH1 hematologic malignancies, leading to approval in frontline and relapsed/refractory (R/R) mIDH1 acute myeloid leukemia. We report final data from a phase 1 single-arm substudy of once-daily ivosidenib in patients with R/R mIDH1 myelodysplastic syndrome (MDS) after failure of standard-of-care therapies. Primary objectives were to determine safety, tolerability, and clinical activity. The primary efficacy end point was the complete remission (CR) + partial remission (PR) rate. Nineteen patients were enrolled; 18 were included in the efficacy analysis. Treatment-related adverse events occurred in 8 (42.1%) patients, including a grade 1 QT interval prolongation in 1 (5.3%) patient and grade 2 differentiation syndrome in 2 (10.5%) patients. Rates of CR + PR and objective response (CR + PR + marrow CR) were 38.9% (95% confidence interval [CI], 17.3-64.3) and 83.3% (95% CI, 58.6-96.4), respectively. Kaplan-Meier estimates showed a 68.6% probability of patients in CR achieving a remission duration of ≥5 years, and a median overall survival of 35.7 months. Of note, 71.4% and 75.0% baseline red blood cell (RBC)- and platelet-transfusion-dependent patients, respectively, became transfusion independent (TI; no transfusion for ≥56 days); 81.8% and 100% of baseline RBC and platelet TI patients, respectively, remained TI. One (5.3%) patient proceeded to a hematopoietic stem cell transplant. In conclusion, ivosidenib is clinically active, with durable remissions and a manageable safety profile observed in these patients. This trial was registered at www.ClinicalTrials.gov as #NCT02074839.
The Femur-First Technique for Oxford Medial Unicompartmental Knee Arthroplasty
Perico, Diego Alarcon, Lee, Sheng‐Hsun , Labott, Josh R. , Perez, Sergio F. Guarin , Sierra, Rafael J. , Alarcon Perico, Diego, Guarin Perez, Sergio F , Sierra, Rafael J , Labott, Joshua R.

JBJS Essential Surgical Techniques | April 19, 2024 | Volume: 14 | Issue: 2 | Pages: No page available

10.2106/jbjs.st.23.00059 | PMID 38645755 Get It

Background: Unicompartmental knee arthroplasty (UKA) is a reliable procedure to treat medial compartment knee osteoarthritis (OA). The reported survivorship of UKA has varied in the literature 3–7 . In part, the higher failure rates of UKA seen in registries could be related to the caseload and experience of the reporting surgeon 8 . The introduction of techniques that make procedures more reliable, especially in the hands of inexperienced surgeons, can decrease the rate of failure. With the Oxford UKA implant (Zimmer Biomet), the recommended surgical technique involves cutting the tibia first, followed by the femoral preparation. However, a technique that allows for preparation of the femur first, as well as the use of the femoral component as a reference for the tibial cut, may reduce the common technical errors seen with the procedure. We have utilized the femur-first technique in cases of medial Oxford UKA. Description: The femur-first method outlined in the present article does not require any unique instruments beyond what is supplied by the manufacturer. Before beginning, the femoral positional guide needs to be decoupled from its base. To start, the intramedullary guide is introduced approximately 1 cm anterior and medial to the intercondylar notch. Once the femoral osteophytes are removed, the surgeon identifies the center of the femoral condyle and marks it. The posterior tibial cartilage is then removed with a saw to facilitate the placement of the appropriately sized femoral spherical guide. The size of the femoral component is determined by selecting the implant that aligns best with the width of the femoral condyle. The femoral drill guide is detached from its base because there is not enough space for the base, as the tibia has not yet been resected. The decoupled femoral guide is connected to the intramedullary rod, allowing the precise positioning of the femoral component in approximately 10° of flexion relative to the femoral sagittal plane and drilling of the 2 peg holes. The posterior condylar resection guide is impacted into position, and the osteotomy of the posterior condyle is made. The distal femur is then milled with use of a number-0 spigot, and the femoral component trial is positioned into place. The femoral condyle is “resurfaced” with the femoral component, which restores joint obliquity and the natural height, a critical element of the femur-first technique. Following this, the 1-mm (size-dependent) spherical gauge is placed around the femoral component trial. The tibial guide is secured with the G-clamp and a number-0 resection block, and is pinned into place. We recommend swapping the number-0 cutting guide for a +2 when making the cut in order to avoid over-resection. Recutting is advised if a minimum 3-mm feeler gauge does not adequately occupy the flexion space. The final step is to balance the flexion and extension gaps in the usual fashion. Alternatives: The alternative technique is a traditional tibia-first approach, in which tibial resection is performed prior to femoral resection. As described in the original manufacturer’s manual, the tibial cut is accomplished with use of a number-0 cutting guide, and the tibial rotation is based on the axis formed by the anterior superior iliac spine and knee center, irrespective of the femoral condyle. Rationale: The femur-first technique is advantageous in several ways. When performing the femoral cut first, the surgeon can better align the drill guide at the center of medial femoral condyle. This will result in the femoral component being positioned more in line with the coronal plane of the femoral condyle. Additionally, the tibial resection is made with the femoral trial in place; therefore, the depth of resection can be more accurate, potentially avoiding excessive bone resection. Finally, with the femoral trial in place, the surgeon can judge the rotation and medial-lateral position of the tibial component more precisely, hence lowering the possibility of bearing spin-out, impingement, and dislocation or unexplained pain. Expected Outcomes: The femur-first technique is a bone-preserving procedure that results in thinner bearings when compared with a tibia-first approach 1 . The femur-first approach also improves radiographic outcomes, including femoral coronal, femoral sagittal, and tibial sagittal alignments, while tibial coronal alignment does not differ. There is an early trend toward improved 5-year survivorship with the femur-first (98%) versus tibia-first (94%, p = 0.35) techniques. There has been no significant difference reported in Knee Society Scores between techniques. Important Tips: Perform a preliminary cut of the posterior tibial cartilage in order to allow insertion of the femoral drill guide under the femoral condyle. Make sure the femoral drill guide lies in the center of the marked medial femoral condyle. Align the tibial sagittal cut with the femoral component trial in order to avoid bearing impingement. Be conservative in the tibial cutting by utilizing a +2 cutting guide (since the coupling is performed with the intramedullary guide in place, which drives the tibial guide distally). Acronyms and Abbreviations: UKA = unicompartmental knee arthroplasty FF = femur-first M-L = medial-lateral AP = anteroposterior PA = posteroanterior ASA = acetylsalicylic acid (aspirin) BID = bis in die, twice a day PT = physical therapy TF = tibia-first FCA = femoral coronal angle FSA = femoral sagittal angle TSA = tibial sagittal angle IM = intramedullary OA = osteoarthritis
TIM-3 + CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies
Minnie, Simone A. , Waltner, Olivia G. , Zhang, Ping , Takahashi, Shuichiro , Nemychenkov, Nicole S, Ensbey, Kathleen S., Schmidt, Christine R. , Legg, Samuel R.W., Comstock, Melissa , Boiko, Julie R. , Nelson, Ethan , Bhise, Shruti S. , Wilkens, Alec B. , Koyama, Motoko , Dhodapkar, Madhav V. , Chesi, Marta , Riddell, Stanley R. , Spencer, Andrew , Green, Damian J , Spencer, Andrew , Furlan, Scott N , Hill, Geoffrey R , Koyama, Motoko , Hill, Geoffrey R.

Science Immunology | April 19, 2024 | Volume: 9 | Issue: 94 | Pages: No page available

10.1126/sciimmunol.adg1094 | PMID 38640253 Get It

Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T PHEX ), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ + T PHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ + T PHEX . We also observed IFN-γ + T PHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19 + leukemia cells. An IFN-γ + T PHEX gene signature was recapitulated in T EX cells from human cancers, including myeloma and lymphoma. Here, we characterize a T EX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T EX found in chronic viral infections. Thus, IFN-γ + T PHEX represent a potential target for immunotherapy of blood cancers.
Applying a Health Equity Lens to Intraoperative Opioid Administration and Postoperative Pain
Milam, Adam J. , Youssef, Mohanad R. , Ugochukwu, Kenechukwu, Hanson, Kristine T. , Raynor, Gwendolyn, Milam, Adam J , Hanson, Kristine , Habermann, Elizabeth B. , Brennan, Emily , Porter, Steven B. , Harbell, Monica W. , Warner, David O.

Anesthesia & Analgesia | April 19, 2024 | Volume: 139 | Issue: 3 | Pages: 675-678

10.1213/ane.0000000000006968 | PMID 38640079 Get It

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11
Stearns, Vered , Jegede, Opeyemi A. , Chang, Victor T. , Skaar, Todd C. , Berenberg, Jeffrey L. , Nand, Ranveer , Shafqat, Atif , Jacobs, Nisha L. , Luginbuhl, William , Gilman, Paul , Benson, Al B. , Goodman, Judie R. , Buchschacher, Gary L. , Henry, N. Lynn , Loprinzi, Charles L. , Flynn, Patrick J. , Mitchell, Edith P. , Chang, Victor T-S , Fisch, Michael J , Sparano, Joseph A , Wagner, Lynne , Jagede, Opeyemi A. , Henry, N Lynn , Stearns, Vered , Fisch, Michael , Sparano, Joseph A. , Wagner, Lynne I.

Clinical Cancer Research | April 19, 2024 | Volume: 30 | Issue: 13 | Pages: 2709-2718

10.1158/1078-0432.ccr-23-2137 | PMID 38640040 Get It

Abstract Purpose: Aromatase inhibitor (AI)–associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a prospective cohort study designed to validate the association between 10 SNPs and AI discontinuation due to AIMSS. Patients and Methods: Postmenopausal women with stage I to III hormone receptor–positive breast cancer received anastrozole 1 mg daily and completed patient-reported outcome measures to assess AIMSS (Stanford Health Assessment Questionnaire) at baseline, 3, 6, 9, and 12 months. We estimated that 40% of participants would develop AIMSS and 25% would discontinue AI treatment within 12 months. Enrollment of 1,000 women with a fixed number per racial stratum provided 80% power to detect an effect size of 1.5 to 4. SNPs were found in ESR1 (rs2234693, rs2347868, and rs9340835), CYP19A1 (rs1062033 and rs4646), TCL1A (rs11849538, rs2369049, rs7158782, and rs7159713), and HTR2A (rs2296972). Results: Of the 970 evaluable women, 43% developed AIMSS and 12% discontinued AI therapy within 12 months. Although more Black and Asian women developed AIMSS than White women (49% vs. 39%, P = 0.017; 50% vs. 39%, P = 0.004, respectively), the AI discontinuation rates were similar across groups. None of the SNPs were significantly associated with AIMSS or AI discontinuation in the overall population or in distinct cohorts. The OR for rs2296972 (HTR2A) approached significance for developing AIMSS. Conclusions: We were unable to prospectively validate candidate SNPs previously associated with AI discontinuation due to AIMSS. Future analyses will explore additional genetic markers, patient-reported outcome predictors of AIMSS, and differences by race.